LCN-2 has recently been proposed as a potential target for psoriasis treatment, since it is involved in keratinocyte differentiation and pathogenesis of psoriasis by stimulating neutrophil function, Th17 activation, and secretion of IL-23 by dendritic cells [11]. Here, IL37 is linked to psoriasis.